Anecdotal Success in Using a Soft Pharmaceutical Regimen to Lower the IL-6 Status in a Patient with Malignant Pleural Mesothelioma
4 months of treatment with a pharmaceutical plan formulated to suppress IL-6 over-expression in one patient has shown first success. Continuation and reproducibility of the effect remain to be seen.
